168 related articles for article (PubMed ID: 27026269)
1. Expression of cell cycle markers is predictive of the response to primary systemic therapy of locally advanced breast cancer.
Tőkés T; Tőkés AM; Szentmártoni G; Kiszner G; Madaras L; Kulka J; Krenács T; Dank M
Virchows Arch; 2016 Jun; 468(6):675-86. PubMed ID: 27026269
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and Clinicopathological Correlations of Cell Cycle Marker Expressions before and after the Primary Systemic Therapy of Breast Cancer.
Tőkés T; Tőkés AM; Szentmártoni G; Kiszner G; Mühl D; Molnár BÁ; Kulka J; Krenács T; Dank M
Pathol Oncol Res; 2020 Jul; 26(3):1499-1510. PubMed ID: 31446607
[TBL] [Abstract][Full Text] [Related]
3. Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value.
Joshi S; Watkins J; Gazinska P; Brown JP; Gillett CE; Grigoriadis A; Pinder SE
BMC Cancer; 2015 Jul; 15():546. PubMed ID: 26205655
[TBL] [Abstract][Full Text] [Related]
4. Assessment of tumour proliferation by use of the mitotic activity index, and Ki67 and phosphohistone H3 expression, in early-stage luminal breast cancer.
van Steenhoven JEC; Kuijer A; Kornegoor R; van Leeuwen G; van Gorp J; van Dalen T; van Diest PJ
Histopathology; 2020 Oct; 77(4):579-587. PubMed ID: 32557844
[TBL] [Abstract][Full Text] [Related]
5. Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy.
Ács B; Zámbó V; Vízkeleti L; Szász AM; Madaras L; Szentmártoni G; Tőkés T; Molnár BÁ; Molnár IA; Vári-Kakas S; Kulka J; Tőkés AM
Diagn Pathol; 2017 Feb; 12(1):20. PubMed ID: 28222768
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of MCM2, Ki-67 and gelsolin in non-small cell lung cancer.
Yang J; Ramnath N; Moysich KB; Asch HL; Swede H; Alrawi SJ; Huberman J; Geradts J; Brooks JS; Tan D
BMC Cancer; 2006 Aug; 6():203. PubMed ID: 16882345
[TBL] [Abstract][Full Text] [Related]
7. Ratio of proliferation markers and HSP90 gene expression as a predictor of pathological complete response in breast cancer neoadjuvant chemotherapy.
Jarzab M; Kowal M; Bal W; Oczko-Wojciechowska M; Rembak-Szynkiewicz J; Kowalska M; Stobiecka E; Chmielik E; Tyszkiewicz T; Kaszuba M; Nowicka E; Lange B; Czarniecka A; Krajewska J; Dyla A; Dobrut M; Lange D; Jarzab B; Bobek-Billewicz B; Tarnawski R
Folia Histochem Cytobiol; 2016; 54(4):202-209. PubMed ID: 28051275
[TBL] [Abstract][Full Text] [Related]
8. The Performance of Ki-67 Labeling Index in Different Specimen Categories of Invasive Ductal Carcinoma of the Breast Using 2 Scoring Methods.
Al Nemer A
Appl Immunohistochem Mol Morphol; 2017 Feb; 25(2):86-90. PubMed ID: 26509909
[TBL] [Abstract][Full Text] [Related]
9. A Comparison of Visual Assessment and Automated Digital Image Analysis of Ki67 Labeling Index in Breast Cancer.
Zhong F; Bi R; Yu B; Yang F; Yang W; Shui R
PLoS One; 2016; 11(2):e0150505. PubMed ID: 26928407
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Proliferation Markers Ki67 and Phosphohistone-H3 (pHH3) in Breast Ductal Carcinoma In Situ.
Bosch DE; Kilgore MR; Schmidt RA; Swanson PE; Rendi MH; Chang OH
Appl Immunohistochem Mol Morphol; 2017 Sep; 25(8):543-547. PubMed ID: 28885232
[TBL] [Abstract][Full Text] [Related]
11. Standardization for Ki-67 assessment in moderately differentiated breast cancer. A retrospective analysis of the SAKK 28/12 study.
Varga Z; Cassoly E; Li Q; Oehlschlegel C; Tapia C; Lehr HA; Klingbiel D; Thürlimann B; Ruhstaller T
PLoS One; 2015; 10(4):e0123435. PubMed ID: 25885288
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical expression of p16INK4A, Ki-67, and Mcm2 proteins in gastrointestinal stromal tumors: prognostic implications and correlations with risk stratification of NIH consensus criteria.
Huang HY; Huang WW; Lin CN; Eng HL; Li SH; Li CF; Lu D; Yu SC; Hsiung CY
Ann Surg Oncol; 2006 Dec; 13(12):1633-44. PubMed ID: 17013685
[TBL] [Abstract][Full Text] [Related]
13. Ki 67 assessment in breast cancer in an Egyptian population: a comparative study between manual assessment on optical microscopy and digital quantitative assessment.
Ayad E; Soliman A; Anis SE; Salem AB; Hu P; Dong Y
Diagn Pathol; 2018 Aug; 13(1):63. PubMed ID: 30153851
[TBL] [Abstract][Full Text] [Related]
14. Minichromosome maintenance protein 2 (MCM2) is a stronger discriminator of increased proliferation in mucosa adjacent to colorectal cancer than Ki-67.
Hanna-Morris A; Badvie S; Cohen P; McCullough T; Andreyev HJ; Allen-Mersh TG
J Clin Pathol; 2009 Apr; 62(4):325-30. PubMed ID: 18474544
[TBL] [Abstract][Full Text] [Related]
15. Ki-67, mini-chromosome maintenance 2 protein (MCM2) and geminin have no independent prognostic relevance for cancer-specific survival in surgically treated squamous cell carcinoma of the penis.
May M; Burger M; Otto W; Hakenberg OW; Wieland WF; May D; Hofstädter F; Götz S; Niessl N; Fritsche HM; Birnkammer K; Gilfrich C; Peter J; Jain A; Koch S; Lebentrau S; Riedmiller H; Rössler W; Denzinger S; Brookman-May S; Gunia S
BJU Int; 2013 Aug; 112(4):E383-90. PubMed ID: 23305250
[TBL] [Abstract][Full Text] [Related]
16. Mitosin and pHH3 predict poorer survival in astrocytomas WHO grades II and III.
Varughese RK; Lind-Landström T; Habberstad AH; Salvesen Ø; Haug CS; Sundstrøm S; Torp SH
J Clin Pathol; 2016 Jan; 69(1):26-34. PubMed ID: 26188054
[TBL] [Abstract][Full Text] [Related]
17. MCM2 expression levels predict diagnosis and prognosis in gastric cardiac cancer.
Liu M; Li JS; Tian DP; Huang B; Rosqvist S; Su M
Histol Histopathol; 2013 Apr; 28(4):481-92. PubMed ID: 23329420
[TBL] [Abstract][Full Text] [Related]
18. Proliferation (Ki-67 and phosphohistone H3) and oncotype DX recurrence score in estrogen receptor-positive breast cancer.
Williams DJ; Cohen C; Darrow M; Page AJ; Chastain B; Adams AL
Appl Immunohistochem Mol Morphol; 2011 Oct; 19(5):431-6. PubMed ID: 21297447
[TBL] [Abstract][Full Text] [Related]
19. The potential value of phosphohistone-h3 mitotic index determined by digital image analysis in the assessment of pancreatic endocrine tumors in fine-needle aspiration cytology specimens.
Draganova-Tacheva R; Bibbo M; Birbe R; Daskalakis C; Solomides C
Acta Cytol; 2013; 57(3):291-5. PubMed ID: 23635399
[TBL] [Abstract][Full Text] [Related]
20. CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance.
Brennan DJ; Jirstrom K; Kronblad A; Millikan RC; Landberg G; Duffy MJ; Rydén L; Gallagher WM; O'Brien SL
Clin Cancer Res; 2006 Nov; 12(21):6421-31. PubMed ID: 17085655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
